Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a 39-year-old woman whose dermatomyositis-systemic lupus erythematosus overlap syndrome symptoms resolved after switching to tofacitinib.

This study found that deletion of c-Jun and JunB in mouse bulge hair follicle stem cells was sufficient to trigger psoriasis-like skin disease through thymic stromal lymphopoietin signaling.

This study found that in Alcorcón, Spain, migrants from Sub-Saharan Africa, the Caribbean, and Latin-America had a higher risk of COVID-19 infection during the first wave compared to Spaniards.

This review examined the role, efficacy, and safety of Janus kinase inhibitors in treating alopecia areata, noting that baricitinib has received approval as the first on-label treatment due to positive outcomes in multiple trials.

This case study describes a severe instance of iatrogenic Cushing's syndrome induced by gamma-hydroxybutyric acid, exacerbated by combined use of betamethasone and anabolic steroids, in an HIV-positive patient on cobicistat-containing therapy.

This review covers potential molecular targets for androgenetic alopecia treatments but presents no new experimental findings; the authors highlight various in vitro and in vivo screening methods for therapeutic compounds.

In this open-label study of post-menopausal women with frontal fibrosing alopecia, researchers found that 12 weeks of baricitinib monotherapy significantly reduced disease activity as measured by the Lichen Planopilaris Activity Index, improved patient-reported scalp hair growth, but showed no significant change in eyebrow growth.

In this study, retrospective analysis of patients with severe alopecia areata showed that oral JAK inhibitors, tofacitinib and baricitinib, reduced hair loss significantly, with comparable effectiveness; longer tofacitinib use was linked to greater improvement, while baricitinib achieved substantial outcomes quickly.

This study suggests that while vitamin D3 deficiency is linked to alopecia areata severity, evidence for the effectiveness of supplementation or topical calcipotriol treatment remains inconsistent and low quality.

This study in a real-world setting found that baricitinib was effectively reducing disease severity in severe alopecia areata patients over 52 weeks, with 37.20% of participants achieving significant improvement and 72.40% experiencing mild or no adverse events.

This review article explores the pathogenesis of vitiligo and examines various therapeutic approaches, specifically highlighting the potential use of oral and topical Janus kinase inhibitors for treatment.

This report highlights Amvuttra's approval for hATTR amyloidosis as a more convenient RNAi therapy, and Olumiant's attention as the first systemic drug for hair loss among recent developments.

This case report describes a 77-year-old woman with female pattern hair loss and elevated testosterone levels, who showed no improvement with minoxidil and lacked adrenal tumors on imaging.

This case report describes a British toddler diagnosed with Kwashiorkor, highlighting that such malnutrition-related disorders are rare in developed countries due to strong socio-economic support systems.

Artemis dysfunction might cause hair loss through telomere shortening.

This research overview highlights that although JAK inhibitors show promise as potential treatments for alopecia areata based on recent insights into the disease mechanism, their efficacy has not yet been thoroughly evaluated in a systematic manner.

This systematic review found that Janus kinase inhibitors have shown beneficial effects for psoriasis and alopecia areata, with promising preliminary results in other skin conditions, though more research is needed to define dosing and safety profiles.

In this study, three patients with extensive alopecia areata showed varying degrees of hair regrowth after 20 weeks of treatment with ustekinumab, a cytokine-targeting therapy.

This review discusses the efficacy and safety of topical JAK inhibitors for inflammatory skin conditions, reporting modest benefits in psoriasis and atopic dermatitis but mixed results for vitiligo and inconclusive data for alopecia areata.

In this phase I study, partial hair regrowth was observed in patients with alopecia universalis using topical JAK inhibitors, though more research is needed to confirm potential as a treatment alternative to clobetasol.

This review discusses the use of tofacitinib as a treatment for plaque psoriasis, highlighting its efficacy and safety in clinical trials, but notes unresolved questions regarding long-term safety.

This review discusses the involvement of type I interferons in skin autoimmune and inflammatory diseases but reports no new clinical results.

This review discusses the application and potential of baricitinib, a JAK1/2 inhibitor, for treating dermatological diseases like alopecia areata and reports no new clinical results.

In this review, researchers discussed recent insights into caspases, enzymes initially associated with cell death and inflammation, revealing their broader roles in cell proliferation, migration, and differentiation, and highlighting the importance of caspase knock-out mice for understanding their implications in diseases.

This source reports that tofacitinib and ruxolitinib showed potential efficacy and acceptable safety profiles in treating various autoimmune disorders, including alopecia areata and psoriasis, based on a review of clinical studies, while recommending physicians consider the individual risks and benefits.

This study describes the positive effects of the JAK inhibitor ruxolitinib in treating autoimmune manifestations in three patients with autoimmune polyendocrine syndrome type-1 over a period of at least 30 months, with excellent tolerance and no adverse events observed.

This review suggests that the gut microbiome and metabolome may play a significant role in alopecia areata and emphasizes the potential of targeting these factors for improved prevention, diagnosis, and treatment strategies for this skin condition.

This review explores the promising but varied effectiveness of tyrosine kinase inhibitors for treating different skin diseases, indicating their potential in dermatology while acknowledging the need for more evidence.

This review highlights the demonstrated efficacy and growing use of upadacitinib for cutaneous disorders, emphasizing its cost-effectiveness and recent availability in India compared to other biologics and small-molecule therapies, rather than providing new primary data.

JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.